Biogen (BIIB) Tops Q4 EPS by 38c, Beats on Revenue; Offers FY26 EPS Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. TSLA
6. META
7. SMCI
8. RTX
9. S
10. COF

Go back to Biogen (BIIB) Tops Q4 EPS by 38c, Beats on Revenue; Offers FY26 EPS Guidance

Biogen earnings preview Q4: set for weaker print, Leqembi outlook in focus

February 6, 2026 2:00 AM EST

Investing.com-- Biogen is set to report a drop in fourth quarter earnings before the market open on February 6 on weaker sales in its multiple sclerosis drugs, although focus will be squarely on the companys pipeline, specifically its Alzheimers treatment Leqembi.

Biogen is expected to post earnings per share of $1.61 on revenue of $2.21 billion for the three months to December 31, Investing.com forecasts showed. This compares to EPS of $3.44 and revenue of $2.45 billion... More